Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03559673 |
|
Expanded Access Status :
Available
First Posted : June 18, 2018
Last Update Posted : June 18, 2018
|
Sponsor:
UCB Biopharma S.P.R.L.
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this Compassionate Use Program (CUP) is to provide continued access to Lacosamide (LCM) for monotherapy use for patients who were receiving LCM in SP0993 and SP0994 at the time of study unblinding and close of SP0994, and who benefited from the treatment per investigator assessment.
| Condition or disease | Intervention/treatment |
|---|---|
| Epilepsies, Partial | Drug: Lacosamide |
| Study Type : | Expanded Access |
| Expanded Access Type : | Treatment IND/Protocol |
| See clinical trials of the intervention/treatment in this expanded access record. | |
| Official Title: | Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0994 Study |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Autosomal dominant partial epilepsy with auditory features
Pyridoxal 5'-phosphate-dependent epilepsy
MedlinePlus related topics:
Seizures
Drug Information available for:
Lacosamide
Intervention Details:
- Drug: Lacosamide
Patients will start on the individual Lacosamide (LCM) dose that they had reached at the completion of the previous monotherapy study. LCM will be administered orally twice daily in 2 divided doses.Other Name: Vimpat
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
Criteria
Inclusion Criteria:
- Patient has completed the Termination Visit of SP0994 and has been treated with Lacosamide (LCM) monotherapy
- Patient is expected to benefit from participation in the Compassionate Use Program (CUP) with LCM monotherapy, in the opinion of the treating physician
- Patient is willing and able to comply with all program requirements
- Patient is informed of the details of this CUP, is given ample time and opportunity to ask questions and consider his/her participation in this CUP, and the patient or the legally authorized representative (LAR) has provided verbal consent to participate, and, if applicable to local regulations, has given written informed consent
Exclusion Criteria:
- Patient is receiving any investigational drugs or using any experimental devices in addition to LCM
- For countries where LCM is reimbursed: Patient requires another anti-epileptic drug (AED) for the treatment of seizures For countries where LCM is not reimbursed (or conditionally reimbursed: Belgium, Australia e.g.): Patient requires another AED for the treatment of seizures and qualifies for commercial LCM (and LCM is being reimbursed)
- Patient experienced emergence of a seizure type other than partial-onset or generalized tonic-clonic seizures, or occurrence of status epilepticus
- Patient developed second- or third-degree atrioventricular (AV) block or another clinically relevant change in medical condition (or electrocardiogram (ECG) or laboratory parameter)
- Patient having liver function test (LFT) results of transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) ≥3×ULN to <5×upper limit of normal (ULN)
- Patient has actual suicidal ideation or behavior
- Patient is experiencing an ongoing serious adverse event (SAE) and there is no expected benefit for him/her to continue on LCM treatment
- Female patient who is pregnant or nursing, and/or a woman of childbearing potential who is not surgically sterile, 2 year postmenopausal or does not practice one highly effective method of contraception (according to ICH guidance defined as those that result in a failure rate of less than 1 % per year when used consistently and correctly), unless sexually abstinent, for the duration of the study
- Patient was treated with carbamazepine controlled release (CBZ-CR) in SP0994
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03559673
Contacts
| Contact: UCB Cares | +1844599 ext 2273 | UCBCares@ucb.com |
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
| Study Director: | UCB Cares | 001 844 599 2273 (UCB) |
| Responsible Party: | UCB Biopharma S.P.R.L. |
| ClinicalTrials.gov Identifier: | NCT03559673 History of Changes |
| Other Study ID Numbers: |
EP0072 |
| First Posted: | June 18, 2018 Key Record Dates |
| Last Update Posted: | June 18, 2018 |
| Last Verified: | June 2018 |
Additional relevant MeSH terms:
|
Seizures Epilepsies, Partial Neurologic Manifestations Nervous System Diseases Signs and Symptoms Epilepsy Brain Diseases |
Central Nervous System Diseases Lacosamide Anticonvulsants Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |